Novel anti-dpep3 antibodies and methods of use
AssigneeAbbvie Stemcentrx LLC
InventorsLaura SAUNDERS, Deepti ROKKAM, David LIU, Mandy BOONTANRART
Life of this patent
Estimating the term…
Abstract
Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
Claims38
An antibody that binds to tumor initiating cells expressing DPEP3.
An isolated antibody that binds to an epitope in a DPEP3 protein, wherein the epitope comprises three or more residues selected from the group consisting of E217, R242, Q248, Q372, K375, and E379 of SEQ ID NO:
- 3.
An isolated antibody that binds to an epitope in a DPEP3 protein, wherein the epitope comprises three or more residues selected from the group consisting of R46, R48, R54, and S55 of SEQ ID NO:
- 3.
An isolated antibody that binds to an epitope in a DPEP3 protein, wherein the epitope comprises three or more residues selected from the group consisting of Q248, S380, S384, and V386 of SEQ ID NO:
- 3.
An isolated antibody that binds specifically to DPEP3 and competes for binding with an antibody comprising:
- a light chain variable region (VL) of SEQ ID NO:
- 21 and a heavy chain variable region (VH) of SEQ ID NO:
- 23;
- or
- a VL of SEQ ID NO:
- 25 and a VH of SEQ ID NO:
- 27;
- or
- a VL of SEQ ID NO:
- 29 and a VH of SEQ ID NO:
- 31;
- or
- a VL of SEQ ID NO:
- 33 and a VH of SEQ ID NO:
- 35;
- or
- a VL of SEQ ID NO:
- 37 and a VH of SEQ ID NO:
- 39;
- or
- a VL of SEQ ID NO:
- 41 and a VH of SEQ ID NO:
- 43;
- or
- a VL of SEQ ID NO:
- 45 and a VH of SEQ ID NO:
- 47;
- or
- a VL of SEQ ID NO:
- 49 and a VH of SEQ ID NO:
- 51;
- or
- a VL of SEQ ID NO:
- 53 and a VH of SEQ ID NO:
- 55;
- or
- a VL of SEQ ID NO:
- 57 and a VH of SEQ ID NO:
- 59;
- or
- a VL of SEQ ID NO:
- 61 and a VH of SEQ ID NO:
- 63;
- or
- a VL of SEQ ID NO:
- 65 and a VH of SEQ ID NO:
- 67;
- or
- a VL of SEQ ID NO:
- 69 and a VH of SEQ ID NO:
- 71;
- or
- a VL of SEQ ID NO:
- 73 and a VH of SEQ ID NO:
- 75;
- or
- a VL of SEQ ID NO:
- 77 and a VH of SEQ ID NO:
- 79;
- or
- a VL of SEQ ID NO:
- 81 and a VH of SEQ ID NO:
- 83;
- or
- a VL of SEQ ID NO:
- 85 and a VH of SEQ ID NO:
- 87;
- or
- a VL of SEQ ID NO:
- 89 and a VH of SEQ ID NO:
- 91;
- or
- a VL of SEQ ID NO:
- 93 and a VH of SEQ ID NO:
- 95;
- or
- a VL of SEQ ID NO:
- 97 and a VH of SEQ ID NO:
- 99;
- or
- a VL of SEQ ID NO:
- 101 and a VH of SEQ ID NO:
- 103;
- or
- a VL of SEQ ID NO:
- 105 and a VH of SEQ ID NO:
- 107;
- or
- a VL of SEQ ID NO:
- 109 and a VH of SEQ ID NO:
- 111;
- or
- a VL of SEQ ID NO:
- 113 and a VH of SEQ ID NO:
- 115;
- or
- a VL of SEQ ID NO:
- 117 and a VH of SEQ ID NO:
- 119;
- or
- a VL of SEQ ID NO:
- 121 and a VH of SEQ ID NO:
- 123;
- or
- a VL of SEQ ID NO:
- 125 and a VH of SEQ ID NO:
- 127;
- or
- a VL of SEQ ID NO:
- 129 and a VH of SEQ ID NO:
- 131;
- or
- a VL of SEQ ID NO:
- 133 and a VH of SEQ ID NO:
- 135;
- or
- a VL of SEQ ID NO:
- 137 and a VH of SEQ ID NO:
- 139;
- or
- a VL of SEQ ID NO:
- 141 and a VH of SEQ ID NO:
- 143;
- or
- a VL of SEQ ID NO:
- 145 and a VH of SEQ ID NO:
- 147;
- or
- a VL of SEQ ID NO:
- 149 and a VH of SEQ ID NO:
- 151;
- or
- a VL of SEQ ID NO:
- 153 and a VH of SEQ ID NO:
- 155;
- or
- a VL of SEQ ID NO:
- 157 and a VH of SEQ ID NO:
- 159;
- or
- a VL of SEQ ID NO:
- 161 and a VH of SEQ ID NO:
- 163;
- or
- a VL of SEQ ID NO:
- 165 and a VH of SEQ ID NO:
- 167;
- or
- a VL of SEQ ID NO:
- 169 and a VH of SEQ ID NO:
- 171;
- or
- a VL of SEQ ID NO:
- 173 and a VH of SEQ ID NO:
- 175;
- or
- a VL of SEQ ID NO:
- 177 and a VH of SEQ ID NO:
- 179;
- or
- a VL of SEQ ID NO:
- 181 and a VH of SEQ ID NO:
- 183;
- or
- a VL of SEQ ID NO:
- 185 and a VH of SEQ ID NO:
- 187.
A humanized antibody that binds to DPEP3 comprising a full length light chain set forth as SEQ ID NO:
- 216 and a full length heavy chain set forth as SEQ ID NO:
- 217;
- or a full length light chain set forth as SEQ ID NO:
- 218 and a full length heavy chain set forth as SEQ ID NO:
- 219;
- or a full length light chain set forth as SEQ ID NO:
- 220 and a full length heavy chain set forth as SEQ ID NO:
- 221;
- or a full length light chain set forth as SEQ ID NO:
- 222 and a full length heavy chain set forth as SEQ ID NO:
- 223;
- or a full length light chain set forth as SEQ ID NO:
- 224 and a full length heavy chain set forth as SEQ ID NO:
- 225;
- or a full length light chain set forth as SEQ ID NO:
- 224 and a full length heavy chain set forth as SEQ ID NO:
- 226;
- or a full length light chain set forth as SEQ ID NO:
- 227 and a full length heavy chain set forth as SEQ ID NO:
- 228;
- or a full length light chain set forth as SEQ ID NO:
- 229 and a full length heavy chain set forth as SEQ ID NO:
- 230.
An ADC of the formula Ab-[L-D]n or a pharmaceutically acceptable salt thereof wherein:
- a) Ab comprises an anti-DPEP3 antibody;
- b) L comprises an optional linker;
- c) D comprises a drug;
- and
- d) n is an integer from about 1 to about 20.
A method of reducing tumor initiating cells in a tumor cell population, wherein the method comprises contacting a tumor cell population comprising tumor initiating cells and tumor cells other than tumor initiating cells, with an anti-DPEP3 ADC;
- whereby the frequency of tumor initiating cells is reduced.
Dependencies are inferred from the claim text.